FZD2 and neoplasm: We investigated the association between FZD2 expression and genomic heterogeneity metrics—including tumor purity, mutant-allele tumor heterogeneity (MATH), tumor mutational burden (TMB), and MSI-as potential biomarkers for immunotherapy response and prognosis.